Delcath Systems Inc. (NASDAQ:DCTH) director Bridget A. Martell sold 22,500 shares of the company's common stock on November 12, 2026, for a total value of $488,508, according to a regulatory filing. The sales followed the exercise of stock options on the same day.
The transaction unfolded in two parts. Martell first disposed of 20,570 shares at prices ranging from $21.20 to $22.19 per share. She then sold an additional 1,930 shares at prices between $22.20 and $22.46 per share. Earlier on November 12, Martell acquired 22,500 shares through the exercise of stock options at $7.85 per share, totaling $176,625. These options vest at a rate of one-twelfth per month, with the first vesting having occurred on May 23, 2024, contingent on her continued service as a director.
Following these transactions, Martell's direct beneficial ownership of Delcath Systems common stock stands at 0 shares.
The timing of the sale is notable. DCTH shares have surged 43% over the past week and are trading near their 52-week high of $22.51. According to an analysis, the stock currently appears overvalued relative to its Fair Value and is in overbought territory.
The insider activity comes on the heels of Delcath's impressive third-quarter 2026 results. The company reported earnings of 17 cents per share, surpassing the forecasted loss of 9 cents per share. Revenue reached a record $35.1 million, significantly exceeding the consensus estimate of $26 million. This growth was driven by $32.7 million from Hepzato and $2.4 million from Chemosat, marking a 72% year-over-year increase in Hepzato volume.
In response to these strong results, Delcath raised its full-year revenue outlook. BTIG subsequently increased its price target for Delcath Systems to $25 from $21, while maintaining a Buy rating. The firm also plans to host investor meetings with Delcath's CEO Gerard Michel and CFO Sandra Pennell in New York City next week.
These developments highlight Delcath's robust financial performance and optimistic future projections. However, the director's sale of her entire direct stake could raise questions about insider confidence, especially given the stock's recent sharp appreciation and overbought status.